Save up -80% on Everolimus

Note: this is a drug discount program, not an insurance plan.
RX BIN: 015558RX PCN: HTGroup ID: DDN6600Card Holder ID: DDN6600
Pharmacists and Patients support.

2019 Price of Afinitor

$14,406.2228 tablets/10 mg
price without discount in nearest pharmacy. Price may vary.

Claim your free Everolimus discount card

We offer free Everolimus coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Everolimus every time. What are you waiting for? Claim your prescription drug card now!

Walgreens pharmacy
Walgreens pharmacy
CVS pharmacy
CVS pharmacy
Walmart pharmacy
Walmart pharmacy
Ride AID pharmacy
Ride AID pharmacy
CVS Target pharmacy
CVS Target pharmacy
Kroger pharmacy
Kroger pharmacy
rx

Get your Prescription

safe

It’s safe and free

pharmacy

Buy drugs in pharmacy

save money

Save money each time

Everolimus volume of distribution

Everolimus pharmacokinetics were best described by a two-compartment model with lag-time (oral clearance = 17.9 L/h; volume of distribution of the central compartment after oral administration [V(1)/F] = 148 L and first-order absorption rate constant [k(a)] = 7.36 h-1).

RX Prescription
Ask Your therapeut before taking any drugs.

About RX24Drugs

2018 Statistics

discount card

Discount Cards 16,000+

benefit

Clients Benefit 29%

savings

Total savings $4,735,080

What is Everolimus

Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus’ effect is solely on the mTORC1 protein and not on the mTORC2 protein.

Everolimus mechanism of action

Everolimus is a mTOR inhibitor that binds with high affinity to the FK506 binding protein-12 (FKBP-12), thereby forming a drug complex that inhibits the activation of mTOR. This inhibition reduces the activity of effectors downstream, which leads to a blockage in the progression of cells from G1 into S phase, and subsequently inducing cell growth arrest and apoptosis. Everolimus also inhibits the expression of hypoxia-inducible factor, leading to a decrease in the expression of vascular endothelial growth factor. The result of everolimus inhibition of mTOR is a reduction in cell proliferation, angiogenesis, and glucose uptake.

Dosage forms of Everolimus

DrugDosageQuantityPrice
Zortress0.25mg60 Tablet$406.00
Zortress0.75mg60 Tablet$1,226.00

Prescription Generics

false

International Brands

Afinitor

Synonyms

40-O-(2-hydroxyethyl)-rapamycin

Manufacturers

Novartis Pharmaceuticals Corporation

CAS number

159351-69-6

UNII

9HW64Q8G6G

State

solid

Affected organisms

Humans and other mammals

Indication of Everolimus

Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole. Indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease. Indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. Indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. Indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.

Toxicity of Everolimus

Potentially life-threatening complications of everolimus and other mTOR inhibitors include pulmonary toxicity. A recently published meta-analysis reported incidence rates of 10.4% and 2.4% for everolimus-induced all-grade and high-grade pulmonary toxicity, respectively. The pathogenesis of the pulmonary toxicity remains unclear. A recent in vivo study suggested that mTOR inhibitors can interact with the STAT1 gene, causing amplification of cellular apoptosis and augmenting lung injury. Although diffuse alveolar hemorrhage (DAH) is a well-recognized manifestation of sirolimus-induced pulmonary toxicity, this complication has been reported only rarely for everolimus.

RX24 Drugs Disclaimer: consult your healthcare provider before buying a Everolimus on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.

Get lower price on Everolimus now!